Opiant Pharmaceuticals, Inc. Common Stock
OPNT
OPNT was delisted on the 1st of March, 2023.
33 hedge funds and large institutions have $22.3M invested in Opiant Pharmaceuticals, Inc. Common Stock in 2022 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 17 increasing their positions, 4 reducing their positions, and 11 closing their positions.
325% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 4
20% less funds holding
Funds holding: 41 → 33 (-8)
33% less capital invested
Capital invested by funds: $33.3M → $22.3M (-$11M)
73% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HP
HealthInvest Partners
Stockholm,
Sweden
|
+$3.1M |
| 2 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$2.46M |
| 3 |
ACA
Apis Capital Advisors
New York
|
+$1.35M |
| 4 |
PHP
Parkman Healthcare Partners
Stamford,
Connecticut
|
+$695K |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$332K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OCM
Ovata Capital Management
Hong Kong
|
-$2.52M |
| 2 |
DAM
DLD Asset Management
New York
|
-$428K |
| 3 |
SM
SG3 Management
Dorado,
Puerto Rico
|
-$345K |
| 4 |
B
Bailard
Foster City,
California
|
-$322K |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$291K |
OPNT Hedge Fund Activity: Q2 2022 in Review
33 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in Opiant Pharmaceuticals, Inc. Common Stock (OPNT) for Q2 2022, worth a combined $22.3M — down 33% from $33.3M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of OPNT and 3 opened new positions — a net loss of 8 holders — while 4 trimmed existing stakes and 17 added.
The largest buyer was HealthInvest Partners, adding an estimated $3.1M. The largest seller was Ovata Capital Management, exiting entirely with an estimated $2.52M sold.
- 33 institutional investors held Opiant Pharmaceuticals, Inc. Common Stock (OPNT) as of Q2 2022, down from 41 in Q1 2022.
- Funds reported $22.3M of Opiant Pharmaceuticals, Inc. Common Stock stock for Q2 2022, down 33% quarter-over-quarter.
- 3 funds opened new Opiant Pharmaceuticals, Inc. Common Stock positions in Q2 2022 and 11 closed out, a net change of -8 holders.
- The largest Opiant Pharmaceuticals, Inc. Common Stock buyer in Q2 2022 was HealthInvest Partners, an estimated $3.1M added.
- The largest Opiant Pharmaceuticals, Inc. Common Stock seller in Q2 2022 was Ovata Capital Management, an estimated $2.52M sold.
Based on aggregated 13F filings for Q2 2022.